Binding molecule specific for Lrig-1 protein and use thereof
AssigneeGood T Cells, Inc.
InventorsJung Ho Kim, Beom Seok Kim
Life of this patent
Estimating the term…
Loading patent…
AssigneeGood T Cells, Inc.
InventorsJung Ho Kim, Beom Seok Kim
Estimating the term…
The present invention relates to a binding molecule capable of specifically binding to Lrig-1 protein, which is located on the surface of a regulatory T cell. The binding molecule provided in the present invention can activate the function of regulatory T cells to effectively prevent, ameliorate, or treat diseases caused by excessive activation or expression of various immune cells and inflammatory cells, for example, immune-related diseases such as autoimmune disease, graft-versus-host disease, organ transplant rejection, asthma, atopy, acute or chronic inflammatory disease, etc. In addition, the binding molecule, preferably the antibody, specific for the Lrig-1 protein according to the present invention has advantages of more effectively targeting the Lrig-1 protein as compared with antibodies against Lrig-1 which are previously commercially available, and also possessing very good binding capacity thereto.
A binding molecule which specifically binds to leucine-rich and immunoglobulin-like domains 1(Lrig-1) protein, wherein the binding molecule is selected from the group consisting of the following (a) to (d):
The method according to 11, wherein the binding molecule further comprises a heavy chain constant region consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs:
Dependencies are inferred from the claim text.